GleamWall
中文EN

ELDN Eledon Pharmaceuticals, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1404281 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-6.6%
TTM EPS YoY-586.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-257.1%
ROA-71.9%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets34.5%
Debt / equity0.00x
Current ratio6.30x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.92x
Accruals ratio-5.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$17.76M$18.23M$17.20M$17.49M$14.97M$20.28M$13.53M$17.93M
SG&A expense$3.91M$4.64M$3.98M$3.99M$4.10M$4.46M$4.43M$6.77M
Operating income-$21.67M-$22.87M-$21.18M—-$19.07M-$24.73M-$17.96M—
Net income-$3.93M-$31.63M-$39.02M-$10.45M-$17.46M-$11.22M-$6.50M-$44.62M
EPS (basic)-0.03-0.27-0.33—-0.21-0.13-0.08—
EPS (diluted)-0.03-0.27-0.33—-0.21-0.13-0.08—
Weighted avg. shares (diluted)114.72M113.63M112.42M—77.16M77.16M77.13M—
Balance sheet
Cash & equivalents$6.88M$6.80M$6.15M$22.81M$3.67M$5.74M$8.50M$20.55M
Short-term investments$62.79M$81.95M$104.94M$110.53M$89.73M$101.83M$116.39M$119.63M
Current assets$73.71M$93.09M$113.57M$135.69M$96.30M$111.40M$127.72M$143.73M
Total assets$106.64M$126.09M$146.67M$169.01M$129.86M$144.91M$161.31M$177.41M
Current liabilities$11.70M$11.79M$13.46M$18.34M$14.30M$13.72M$9.19M$11.58M
Total liabilities$36.83M$54.06M$46.21M$32.23M$38.80M$38.88M$46.73M$59.27M
Shareholders' equity$30.80M$33.01M$44.76M$81.08M$35.36M$50.33M$58.89M$62.45M
Shares outstanding81.44M80.89M75.85M75.43M59.88M59.88M59.88M59.79M
Cash flow statement
Operating cash flow-$18.98M-$22.68M-$22.61M-$14.09M-$14.48M-$17.71M-$16.06M-$18.99M
Investing cash flow$19.33M$23.24M$5.96M-$20.46M$12.40M$14.96M$3.89M-$47.38M
Financing cash flow-$271,000——$53.69M$0$0$115,000$80.17M
Stock-based compensation$1.92M$3.15M$2.20M$2.46M$2.43M$2.69M$2.86M$6.58M

Free plan shows the latest 8 periods; Pro shows all 55 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.